141 related articles for article (PubMed ID: 35630655)
1. Recovery of
Kazakov AG; Ekatova TY; Babenya JS; Belyshev SS; Khankin VV; Kuznetsov AA; Vinokurov SE; Myasoedov BF
Molecules; 2022 May; 27(10):. PubMed ID: 35630655
[TBL] [Abstract][Full Text] [Related]
2. Activation of natural Hf and Ta in relation to the production of 177Lu.
Medvedev DG; Mausner LF; Greene GA; Hanson AL
Appl Radiat Isot; 2008 Oct; 66(10):1300-6. PubMed ID: 18456503
[TBL] [Abstract][Full Text] [Related]
3. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
4. Excitation function for deuteron induced nuclear reactions on natural ytterbium for production of high specific activity 177g Lu in no-carrier-added form for metabolic radiotherapy.
Manenti S; Groppi F; Gandini A; Gini L; Abbas K; Holzwarth U; Simonelli F; Bonardi M
Appl Radiat Isot; 2011 Jan; 69(1):37-45. PubMed ID: 20801665
[TBL] [Abstract][Full Text] [Related]
5. Indirect Production of No Carrier Added (NCA) (177)Lu from Irradiation of Enriched (176)Yb: Options for Ytterbium/Lutetium Separation.
Dash A; Chakravarty R; Knapp FF; Pillai AM
Curr Radiopharm; 2015; 8(2):107-18. PubMed ID: 25771377
[TBL] [Abstract][Full Text] [Related]
6. Physical optimization of production by deuteron irradiation of high specific activity (177g)Lu suitable for radioimmunotherapy.
Manenti S; Bonardi ML; Gini L; Groppi F
Nucl Med Biol; 2014; 41(5):407-9. PubMed ID: 24666720
[TBL] [Abstract][Full Text] [Related]
7. Production of No-Carrier Added Lutetium-177 by Irradiation of Enriched Ytterbium-176.
Tarasov VA; Andreev OI; Romanov EG; Kuznetsov RA; Kupriyanov VV; Tselishchev IV
Curr Radiopharm; 2015; 8(2):95-106. PubMed ID: 25771378
[TBL] [Abstract][Full Text] [Related]
8. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
Abbasi IA
Nucl Med Biol; 2011 Apr; 38(3):417-25. PubMed ID: 21492790
[TBL] [Abstract][Full Text] [Related]
9. Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.
Bhardwaj R; van der Meer A; Das SK; de Bruin M; Gascon J; Wolterbeek HT; Denkova AG; Serra-Crespo P
Sci Rep; 2017 Mar; 7():44242. PubMed ID: 28287131
[No Abstract] [Full Text] [Related]
10. Characteristics of Bremsstrahlung emissions of (177)Lu, (188)Re, and (90)Y for SPECT/CT quantification in radionuclide therapy.
Uribe CF; Esquinas PL; Gonzalez M; Celler A
Phys Med; 2016 May; 32(5):691-700. PubMed ID: 27157626
[TBL] [Abstract][Full Text] [Related]
11. Radionuclide generator-based production of therapeutic
Bhardwaj R; Wolterbeek HT; Denkova AG; Serra-Crespo P
EJNMMI Radiopharm Chem; 2019 Jul; 4(1):13. PubMed ID: 31659496
[TBL] [Abstract][Full Text] [Related]
12. Technical note: Assessment of radiation measurement devices for the detection of [
Kupitz D; Einspänner E; Wissel H; Hohn A; Kreissl MC; Grosser OS
Med Phys; 2023 Jan; 50(1):590-599. PubMed ID: 36208077
[TBL] [Abstract][Full Text] [Related]
13. Investigation of Radiolabeling Efficacy by Enhancement of the Chemical form of no Carrier Added
Vosoughi S; Salek N; Arani SS; Samani AB; Maragheh MG
Curr Radiopharm; 2022; 15(1):56-62. PubMed ID: 33480353
[TBL] [Abstract][Full Text] [Related]
14. Production, quality control, and determination of human absorbed dose of no carrier added
Salek N; Mehrabi M; Shirvani Arani S; Bahrami Samani A; Erfani M; Vosoghi S; Ghannadi Maragheh M; Shamsaei M
J Labelled Comp Radiopharm; 2017 Jan; 60(1):20-29. PubMed ID: 27862203
[TBL] [Abstract][Full Text] [Related]
15. Preliminary studies on (177)Lu-labeled sodium pyrophosphate (177Lu-PYP) as a potential bone-seeking radiopharmaceutical for bone pain palliation.
Abbasi IA
Nucl Med Biol; 2012 Aug; 39(6):763-9. PubMed ID: 22459337
[TBL] [Abstract][Full Text] [Related]
16. Isolation of a 177Hf complex formed by beta-decay of a 177Lu-labeled radiotherapeutic compound and NMR structural elucidation of the ligand and its Lu and Hf complexes.
Cagnolini A; D'Amelio N; Metcalfe E; Nguyen HD; Aime S; Swenson RE; Linder KE
Inorg Chem; 2009 Apr; 48(7):3114-24. PubMed ID: 19243162
[TBL] [Abstract][Full Text] [Related]
17. Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints.
Chakraborty S; Das T; Banerjee S; Sarma HD; Venkatesh M
Nucl Med Commun; 2006 Aug; 27(8):661-8. PubMed ID: 16829766
[TBL] [Abstract][Full Text] [Related]
18. A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Therapeutic Isotopes.
Gholami YH; Josephson L; Akam EA; Caravan P; Wilks MQ; Pan XZ; Maschmeyer R; Kolnick A; El Fakhri G; Normandin MD; Kuncic Z; Yuan H
Int J Nanomedicine; 2020; 15():31-47. PubMed ID: 32021163
[TBL] [Abstract][Full Text] [Related]
19. The low-energy β(-) and electron emitter (161)Tb as an alternative to (177)Lu for targeted radionuclide therapy.
Lehenberger S; Barkhausen C; Cohrs S; Fischer E; Grünberg J; Hohn A; Köster U; Schibli R; Türler A; Zhernosekov K
Nucl Med Biol; 2011 Aug; 38(6):917-24. PubMed ID: 21843788
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging.
Gleisner KS; Brolin G; Sundlöv A; Mjekiqi E; Östlund K; Tennvall J; Larsson E
J Nucl Med; 2015 Jul; 56(7):976-84. PubMed ID: 25999429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
